Albumin nanostructure assisted ABZ anti-parasite immune therapy for T. spiralis muscle infection
Source abstract
Abstract
Currently, the treatment of Trichinella spiralis (T. spiralis) intracellular infection by oral administration of albendazole (ABZ) is hampered by its poor aqueous solubility and rapid metabolism. Herein, the nanoparticles with BSA and ABZ (ABZ-BSA Nps) were constructed by a desolvation technique in the study. The anti-parasite activity and pharmacokinetics of ABZ-BSA Nps were evaluated for T. spiralis muscle larvae during the encysted phase. The immune-responsive cytokines of ABZ-BSA Nps were quantitatively analyzed. The results showed that ABZ-BSA Nps could eliminate the muscle larvae by triggering the unbalance of Th1/Th2 immune-response in the infection mice. For ABZ-BSA Nps treatment group, the plasma concentration of ABZSO (ABZ active metabolite) was higher than ABZ and the muscle larvae were reduced by 70.2 %. In conclusion, the study had constructed a successful prospective protein nanoparticle delivery ABZ and evidenced the ABZ could be used for intracellular parasite therapy by triggering the anti-parasite immunity of hosts.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Parasitic Diseases Research and Treatment · Parasite Biology and Host Interactions · Parasites and Host Interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Emerging food-borne parasites10.1016/j.vetpar.2009.05.026 ↗
2. Trichinellosis
3. Current research of trichinellosis in China10.3389/fmicb.2017.01472 ↗
4. A novel formulation of albendazole solution: oral bioavailability and efficacy evaluation10.1016/S0378-5173(97)00204-4 ↗
5. Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy10.1016/0169-4758(90)90232-S ↗
6. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer10.1007/s00280-009-1157-8 ↗
7. Nanoformulations of albendazole as effective anticancer and antiparasite agents10.2217/nnm-2017-0102 ↗
8. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole10.1016/S0304-3835(01)00382-2 ↗
9. Albendazole sensitizes cancer cells to ionizing radiation10.1186/1748-717X-6-160 ↗
10. The efficacy of therapy with albendazole in mice with parasitic meningitis caused by Angiostrongylus cantonensis10.1007/s00436-004-1105-9 ↗
11. Albendazole therapy for eosinophilic meningitis caused by Angiostrongylus cantonensis10.1007/s00436-006-0405-7 ↗
12. Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation10.1136/jitc-2021-003819 ↗
13. Effect of treatment with free and liposomized albendazole on selected immunological parameters and cyst growth in mice infected with echinococcus multilocularis10.1016/j.parint.2004.05.001 ↗
14. The combination of cytokines and albendazole therapy for prophylaxis and treatment of experimental/hydatid cyst10.1016/j.actatropica.2019.105206 ↗
15. T-cell subsets (Th1 versus Th2)10.1016/S1081-1206(10)62426-X ↗
16. T cells involved in psoriasis vulgaris belong to the Th1 subset10.1111/1523-1747.ep12371752 ↗
17. CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC). III. CD4+ cytotoxic T cells induce apoptosis of APC10.1002/eji.1830220139 ↗
18. A novel receptor involved in T-cell activation10.1038/376260a0 ↗
19. Dendritic cell regulation of T helper cells10.1146/annurev-immunol-101819-025146 ↗
20. The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications10.3390/cells10123397 ↗
21. Submerged cultivation of ganoderma lucidum and the effects of its polysaccharides on the production of human cytokines TNF-α, IL-12, IFN-γ, IL-2, IL-4, IL-10 and IL-1710.1016/j.nbt.2014.07.007 ↗
22. Comparative interleukin (IL-2)/interferon IFN-gamma and IL-4/IL-10 responses during acute infection of macaques inoculated with attenuated nef-truncated or pathogenic SICmac251 virus10.1073/pnas.93.8.3658 ↗
23. Trichinella spiralis: inflammation modulator10.1017/S0022149X20000802 ↗
24. Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers10.1128/AAC.48.3.1051-1054.2004 ↗
25. Bovine serum albumin nanoparticles as controlled release carrier for local drug delivery to the inner ear10.1186/1556-276X-9-343 ↗
26. Albumin-based nanoparticles as potential controlled release drug delivery systems10.1016/j.jconrel.2011.07.031 ↗
27. Synthesis, photophysical and photobiological characterization of BSA nanoparticles loaded with chloroaluminium phthalocyanine by one-step desolvation technique for photodynamic therapy action10.1080/09205063.2019.1650241 ↗
28. Presumptive albendazole toxicosis in 12 alpacas10.1111/j.1939-1676.2009.0324.x ↗
29. A nanotherapy responsive to the inflammatory microenvironment for the dual-targeted treatment of atherosclerosis, nanomedicine: nanotechnology
30. Polyreactive broadly neutralizing b cells are selected to provide defense against pandemic threat influenza viruses10.1016/j.immuni.2020.10.005 ↗
31. Albendazole treatment in laying hens: egg residues and its effects on fertility and hatchability10.1111/jvp.12675 ↗
32. In vitro evaluation of albendazole-loaded nanostructured lipid carriers on echinococcus granulosus microcysts and their prophylactic efficacy on experimental secondary hydatidosis10.1007/s00436-021-07343-0 ↗
33. Performance of doxorubicin-conjugated gold nanoparticles: regulation of drug location10.1021/acsami.6b16669 ↗
34. Feeding management and albendazole pharmacokinetics in pigs
35. Nanoscale coordination polymers for synergistic NO and chemodynamic therapy of liver cancer10.1021/acs.nanolett.9b01093 ↗
36. Sensitivity and optimization of artificial digestion in the inspection of meat for Trichinella spiralis10.1089/fpd.2009.0445 ↗
37. A metalloproteinase Tsdpy31 from trichinella spiralis participates in larval molting and development10.1016/j.ijbiomac.2021.10.021 ↗
38. Comparison of artificial digestion and Baermann's methods for detection of trichinella spiralis pre-encapsulated larvae in muscles with low-level infections10.1089/fpd.2011.0985 ↗
39. Immune cell responses and cytokine profile in intestines of mice infected with trichinella spiralis10.3389/fmicb.2017.02069 ↗
40. A. Rke B. Dsa A. Eae A. Gmem A. Mfa n.d. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis - ScienceDirect, Carbohydr. Polym. 232.
41. Atomic-resolution structure of HIV-1 capsid tubes by magic-angle spinning NMR10.1038/s41594-020-0489-2 ↗
42. The blood-cerebrospinal fluid barrier features different permeability to Cyanidin-3-galactoside and Cyanidin-3-diglucoside-5-glucoside and their metabolites circulating in blood10.1021/acs.jafc.2c03778 ↗
43. Soft surface nanostructure with semi-free polyionic components for sustainable antimicrobial plastic10.3390/ijms222212315 ↗
44. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model10.1186/s12951-015-0082-8 ↗
45. Comparative proteomics analysis of trichinella spiralis muscle larvae exposed to albendazole sulfoxide stress10.1016/j.actatropica.2017.12.023 ↗